Next-Generation Biologics Market 2018-2028 - Visiongain Report
LONDON, March 16, 2018 /PRNewswire/ --
Revenue Forecasts and R&D Trends for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
Report Details
Next Generation Biologics Market Report 2018-2028 [https://www.visiongain.com/Report/2148/Next-Generation-Biologics-Market-2018-2028 ]: Forecasts by Market and Segments - Do you need definitive Next Generation Biologics market data? - Do you want to understand clear demarcation between next generation biologics and traditional biologics? - Next Generation Biologics and sub-segment market analysis? - Key drivers and constrains accompanied by this market? - Clear leaders and lagers? - Next wave of blockbusters and drivers impacting them?
Read on to discover how this definitive report can transform your own research and save you time. The introduction of new pipeline drugs in Next generation biologics [https://www.visiongain.com/Report/2148/Next-Generation-Biologics-Market-2018-2028 ], has led visiongain [http://www.visiongain.com ] to publish this timey report. The Next generation biologics market is expected to flourish in the next few years because of emergence of new phase III as well as marketed candidates which are going change the course of the market. Not only new candidates, but the technology (drug delivery as well as the mechanism of action) are novel which make the report a worth find and insightful.
Report highlights
- 140 quantitative tables, charts, and graphs
- Analysis of key players in Next generation biologics Market - Abbvie - Roche/ Genentech - Amgen - GSK - Eli Lilly - Sanofi Aventis - Novo Nordisk - Seattle Genetics
- Global next generation biologics market [https://www.visiongain.com/Report/2148/Next-Generation-Biologics-Market-2018-2028 ] outlook and analysis from 2018-2028
- Regional Next generation biologics market forecasts from 2018-2028 - US forecast 2018-2028, - Japan forecast 2018-2028 - India forecast 2018-2028 - Germany forecast 2018-2028 - UK forecast 2018-2028 - France forecast 2018-2028 - Italy forecast 2018-2028 - Spain forecast 2018-2028 - China forecast 2018-2028
- Key questions answered - What does the future hold for the next generation biologics? - Where should you target your business strategy? - Which applications should you focus upon? - Which disruptive technologies should you invest in? - Which companies should you form strategic alliances with? - Which company is likely to success and why? - What business models should you adopt? - What industry trends should you be aware of?
- Target audience - Leading Pharmaceutical companies - Suppliers - Contractors - Technologists - R&D staff - Consultants - Analysts - CEO's - CIO's - COO's - Business development managers - Investors - Governments - Agencies - Industry organisations - Banks
To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100
Or click on: https://www.visiongain.com/Report/2148/Next-Generation-Biologics-Market-2018-2028
Companies Mentioned in the Report
3SBio
Aastrom Biosciences (now Vericel Corporation)
AbbVie
Abcam
Ablynx
ADC Therapeutics
Adnexus (part of Bristol-Myers Squibb)
Adocia
Advanced Cell Technology (now Ocata Therapeutics)
Advantagene
Affibody
Agensys (now part of Astellas Pharma)
Alcon (part of Novartis)
Alexion Pharmaceuticals
Alfacell (now Tamir Biotechnology)
Alkermes
Allergan
Allozyne
Ambrx
Amgen
AMRI
AnGes
Applied Genetic Technologies (AGTC)
Ark Therapeutics
Astellas Pharma
AstraZeneca
Athersys
Avita Medical
Baxter International
Bayer Healthcare
Belrose Pharma
Benda Pharmaceutical
Biocad
BioCancell Therapeutics
Biocon
Biodel
Biogen Idec
Bioheart
BioMarin Pharmaceutical
Biopartners (part of Bioton)
Biotest Pharmaceuticals
Bioton
BioVex Group (part of Amgen)
BioWa (part of Kyowa Hakko Kirin)
bluebird bio
Boehringer Ingelheim
BrainStorm Cell Therapeutics
Bristol-Myers Squibb
Capricor Therapeutics
Cardio3 BioSciences
Cardium Therapeutics
Catalent Pharma Solutions
Celgene
Celladon
CellCoTec
Celldex Therapeutics
Cellerant Therapeutics
Cellular Dynamics International (CDI)
Cephalon (part of Teva)
CEPiA (part of Sanofi)
Ceregene
Chatham Therapeutics
Chiesi Farmaceutici
Chugai (part of Roche)
Civitas Therapeutics
Clayton Biotechnologies
Cold Genesys
Concortis
Covagen
Crescendo Biologics
Critical Pharmaceuticals
CSL Behring
CytoMedix
Cytori Therapeutics
Dance Biopharm
Delenex Therapeutics
Depuy Mitek (part of J&J)
Diabetology
Diasome Pharmaceuticals
Dr. Reddy's Laboratories
Dyax
Eddingpharm
EGEN
Eisai
Elan Pharmaceuticals (now part of Perrigo Company)
Eli Lilly
Emisphere
Enzon Pharmaceuticals
EnzymeRx
Epitomics (part of Abcam)
ESBATech (part of Novartis)
Flamel Technologies
Fresenius Biotech (now named Neovii Biotech, part of Neopharm)
Fuji Pharma
Fujifilm Diosynth Biotechnologies
Gamida Cell
Genentech (part of Roche)
Generex Biotechnology
Genmab
Genzyme (part of Sanofi)
Geron
GlaxoSmithKline (GSK)
GlycoExpress
Glycotope
Halozyme Therapeutics
Hanmi Pharmaceutical
Health Canada
Hikma Pharmaceuticals
Histogenics
Humacyte
Human Stem Cells Institute (HSCI)
Igenica
ImmunoGen
Immunomedics
Innovent Biologics
Integra LifeSciences
Introgen Therapeutics
Jain Foundation
JCR Pharmaceuticals
Johnson & Johnson (J&J)
Juventas Therapeutics
Karolinska Institute
Kyowa Hakko Kirin
LG Life Sciences
LifeCell
Lonza
Loyola University
MacroGenics
MannKind
MedImmune (part of AstraZeneca)
Merck & Co.
Merck KGaA
Merck Serono
Merrimack Pharmaceuticals
Merrion Pharmaceuticals
Mersana Therapeutics
Mesoblast
Micromet (part of Amgen)
Millennium Pharmaceuticals
Mitsubishi Tanabe Pharma
Mochida Pharmaceutical
Molecular Partners
MorphoSys
Nektar Therapeutics
Neopharm Group
NeoStem
NeuralStem
Nippon Kayaku
Novartis
Novo Nordisk
Nuron Biotech
NuVasive
Ocata Therapeutics (formerly Advanced Cell Technology)
OncoSec Medical
OPKO Health
Oramed Pharmaceuticals
Organogenesis
Organovo
Orthofix
Osiris Therapeutics
PeriphaGen Holdings
Perrigo Company
Pfizer
Pieris
Piramal Group
Progenics Pharmaceuticals
Prolor Biotech (part of OPKO Health)
Rani Therapeutics
ratiopharm (part of Teva)
Redwood Bioscience
Regeneron Pharmaceuticals
Reliance Life Sciences
ReNeuron
RIKEN [Japan]
Roche
Roche Glycart (part of Roche)
SAFC
Sandoz (part of Novartis)
Sanofi
Seattle Genetics
Shanghai Sunway Biotech
Shenzhen SiBiono GeneTech (part of Benda)
Shreya Life Sciences
SironRX Therapeutics
Skye Orthobiologics
Sorrento Therapeutics
Sotex PharmFirm
Spark Therapeutics
Spectrum Pharmaceuticals
Spirogen (part of AstraZeneca)
Stelis Biopharmaceuticals (part of Strides Arcolab)
Stem CentRx
StemCells
Stempeutics Research
Strativa Pharmaceuticals
Strides Arcolab
Sutro Biopharma
Swedish Orphan Biovitrum (Sobi)
Symphogen
Synthon
Synthon Biopharmaceuticals BV (part of Synthon)
Takeda Pharmaceutical Company
Teva Pharmaceutical Industries
Thermalin Diabetes
TiGenix
TRION Pharma
UCB
UniQure
USV
VBL Therapeutics
Vericel Corporation
Versartis
viDA Therapeutics
Viventia Biotechnologies Inc
VX Pharma
Wyeth (part of Pfizer)
Xencor
Xeris Pharmaceuticals
Zydus Cadila
To see a report overview please email Sara Peerun on sara.peerun@visiongain.com
Photo:
http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg
SOURCE Visiongain
